Medication management of chronic heart failure in older adults

Drugs and Aging

Volumn 30, Issue 10, 2013, Pages 765-782

  Alagiakrishnan, Kannayiram ^a   Banach, Maciej ^b   Jones, Linda G ^c,d   Ahmed, Ali ^c,d   Aronow, Wilbert S ^e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE A1 RECEPTOR ANTAGONIST; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; IVABRADINE; LOOP DIURETIC AGENT; MEMBRANE METALLOENDOPEPTIDASE; METOLAZONE; MINERALOCORTICOID ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN; VASOPRESSIN ANTAGONIST;

ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; COUGHING; DIURETIC THERAPY; EVIDENCE BASED PRACTICE; GERIATRIC DISORDER; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; KIDNEY ARTERY STENOSIS; MORBIDITY; MORTALITY; PHARMACOGENETICS; PRIORITY JOURNAL; QUALITY OF LIFE;

AGED; CHRONIC DISEASE; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART FAILURE; HUMANS;

EID: 84890132943     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0105-9     Document Type: Article

References (148)

1. Lloyd-Jones D, Adams RJ, Brown T, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-215.
2. WHO definition of an older or elderly person. http://www.who.int/ healthinfo/survey/agingdefnolder/en/index.html. Accessed 20 Jan 2013.
3. Lloyd-Jones D, Adams R, Carnethon M, for the American Heart Association Statistics Committee and Stroke Stastistics Subcommitee, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-181.
4. McMurray JJV, Stewart S. The burden of heart failure. Eur Heart J Suppl. 2002;4:D50-8.
5. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348(2007-1):8.
6. Mahjuub H, Rusimaru D, Souliere V, Durier C, Peltier M, Tribouilloy C. Long- term survival in patients older than 80 years hospitalized for heart failure: a 5-year prospective study. Eur J Heart Fail. 2008;10:78-84.
7. Incidence and Prevalence: 2006 chart book on cardiovascular and lung diseases. Bethesda, Maryland, USA: National Institute of Health, National Heart, Lung and Blood Institute, p. 73.
8. Komajda M, Hanon O, Hochadel M, et al. Management of octogenarians hospitalized for heart failure in Euro heart failure survey I. Eur Heart J. 2007;28:1310-8. (Pubitemid 47355968)
9. Lien CT, Gillespie ND, Struthers AD, Mcmurdo ME. Heart failure in frail elderly patients: diagnostic difficulties, co- morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail. 2002;4:91-8. (Pubitemid 34113333)
10. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550-6.
11. Phan TT, Shivu GN, Abozguia K, et al. The pathophysiology of heart failure with preserved ejection fraction: from molecular mechanisms to exercise haemodynamics. Int J Cardiol. 2012;158:337-43.
12. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;110:e391-479.
13. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387-95. (Pubitemid 28363803)
14. Aronow WS. Heart Failure update: treatment of heart failure with a normal left ventricular ejection fraction in the elderly. Geriatrics. 2006;61(8):16-20. (Pubitemid 44267072)
15. Tsutsui T, Tsutamoto T, Maeda K, Kinoshita M. Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure. J Cardiovasc Pharmacol 2001;38:(Suppl.1):581-85.
16. Hisatake S, Nanjo S, Fujimoto S, et al. Comparative analysis of the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic heart failure using 125 I-metaiodobenzylguanidine scintigraphy. Eur J Heart Fail. 2011;13:892-8.
17. Ahmed A, Young JB, Love TE, et al. A propensity matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol. 2008;125:246-53. (Pubitemid 351400220)
18. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17. (Pubitemid 29407370)
19. Donaski M, Tian X, Haigney M, Pitt B. Diuretic use, progressive heart failure and death in patients in the DIG study. J Card Fail. 2006;12:327-32. (Pubitemid 43817590)
20. Masuyama T, Tsujino T, Origasa H, et al. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure: the J-Melodic study. Circ J. 2012;76:833-42.
21. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev 2012;15(2):2; CD003638. doi: 10.1002/14651858: CD003838:pub.3.
22. Jentzer JC, Dewald TA, Hernandez AF. Combination of loop-diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527-34.
23. Sica DA. Metalazone and its role in edema management. Congest Heart Failure. 2007;9:100-5.
24. Rosenberg J, Gustafsson F, Galatius S, Hildebrant PR. Combination therapy with metalazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005;19:301-6. (Pubitemid 41778811)
25. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
26. Ezekowitz JA, Mc Allister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J. 2009;30:469-77.
27. Zannad F, Stoug WG, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: intergrating evidence into clinical practice. Eur Heart J. 2012;33:2782-95.
28. Yamaji M, Tsutamato T, Kawahara C, et al. Effect of epleronone versus spironolactone on cortisol and HbA1c levels in patients with chronic heart failure. Am Heart J. 2010;160:915-21.
29. Roongsritong C, Sutthiwan P, Bradley J, et al. Sprinolactone improves diastolic function in the elderly. Clin Cardiol. 2005;28:484-7. (Pubitemid 41434276)
30. Alagiakrishnan K, Banach M, Jones LG, et al. Update on diastolic heart failure with preserved ejection fraction in the older adults. Ann Med. 2013;45:37-50.
31. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with preserved ejection fraction (The Aldo-DHF randomized controlled trial). JAMA. 2013;309(8):781-91.
32. Bielecka-Dabrowa A, Mikhailidis DP, Jones L, Rysz J, Aronow WS, Banach M. The meaning of hypokalemia in heart failure. Int J Cardiol. 2012;158(1):12-7.
33. Bielecka-Dabrowa A, Rysz J, Mikhailidis DP, Banach M. What is the risk of hyperkalaemia in heart failure? Expert Opin Pharmacother. 2011;12(15):2329-38.
34. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-5. (Pubitemid 29440124)
35. Bowling CB, Pitt B, Ahmed MI, et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010;3(2):253-60.
36. Cruz CS, Cruz DA, Marcilio DE, Souza CA. Hyperkalemia in congestive heart failure patients using ACE inhibitors and spirinolactone. Nephrol Dial Transpl. 2003;18:1814-9. (Pubitemid 37098553)
37. Pitt B, Bakris G, Ruilope LM, et al. On behalf of the EPHESUS investigators. Serum potassium and clinical outcomes in the Eplerenone Post-acute myocardial infarction Heart failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118:1643-50.
38. Muzzarelli S, Maeder MT, Toggweiler S, et al. Frequency and predictors of hyperkalemia in patients >60 years of age with heart failure undergoing intense medical therapy. Am J Cardiol. 2012;109(5):693-8.
39. Sica DA, Gehr TWB, Frishman WH. Use of diuretics in the treatment of heart failure in the elderly. Heart Fail Clin J. 2007;3:455-64. (Pubitemid 47465102)
40. Matsuzaki M, Hori M, Izumi T, Furunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl. 1):S33-45.
41. Aronow WS. Treatment of systolic and diastolic heart failure in the elderly. J Am Med Dir Assoc. 2006;7:29-36. (Pubitemid 43229466)
42. Dinsdale C, Wani M, Steward J, et al. Tolerability of sprinolactone as an adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing. 2005;34:395-8. (Pubitemid 41511325)
43. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991;325:293-302.
44. Cohn NJ, Tognoni G, for the Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan on chronic heart failure. N Engl J Med. 2001;345:1667-75. (Pubitemid 33126822)
45. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function, intolerant to angiotensin-converting-enzyme inhibitors: The CHARM ALTERNATIVE trial. Lancet. 2003;362:772-6. (Pubitemid 37093917)
46. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure randomized trial - The Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-7. (Pubitemid 30240502)
47. Dickstein K, Kjershus J, OPTIMAAL steering committee of the OPTIMAAL study group. Effects of losartan and captopril on mortality and morbidity in high risk patients after acute myocardial infarction: The OPTIMAAL randomized trial. Optimal trial in Myocardial Infarction with Angiotensin II antagonist Losartan. Lancet. 2002;360(9335):752-60. (Pubitemid 35247704)
48. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, capropril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med. 2003;349(20):1893-906. (Pubitemid 37409706)
49. Gambassi G, Lapane KL, Sgadari A, Carbonin P, Gatsonis C, Lipsitz LA, Mor V, Bernabei R. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. Arch Intern Med. 2000;160:53-60. (Pubitemid 30040973)
50. Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo MET. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart. 2002;88:373-7.
51. Ahmed A, Eiefe CI, Allman RM, et al. Survival benefits of angiotensin converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc. 2002;50:1659-66. (Pubitemid 35192537)
52. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patient with ACE-inhibitor induced angioedema. Ann Pharmacother. 2000;34:526-8. (Pubitemid 30193787)
53. Mc Murray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet. 2003;362:767-71. (Pubitemid 37093916)
54. White HD, Aylward PE, Huang Z, et al. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation. 2005;112:3391-9. (Pubitemid 43739553)
55. Kasama S, Toyama T, Sumino H, et al. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med. 2007;48:1993-2000. (Pubitemid 350232308)
56. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol. 1993;71:602-4. (Pubitemid 23065018)
57. Kitzman DW, Hundley WG, Brubaker PH, et al. A randomized double-blind trail of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and aortic distensibility. Circ Heart Fail. 2010;3(4):477-85.
58. Massie BM, Carson PE, Mcmurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-67.
59. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM Preserved Trial. Lancet. 2003;362:777-81. (Pubitemid 37093918)
60. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-45. (Pubitemid 44453578)
61. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor nerpilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double blind randomized controlled trial. Lancet. 2012;380:1387-95.
62. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ 696, a novel dual- acting angiotensin receptor neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401-14.
63. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138:917-24. (Pubitemid 38124634)
64. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet. 2002;360:1631-9. (Pubitemid 35379734)
65. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexitil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139:609-17. (Pubitemid 30207785)
66. McMurray J, Cohen-Solai A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail. 2001;3:495-502. (Pubitemid 32780528)
67. Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, Guichard JL, Aban I, Love TE, Aronow WS, White M, Deedwania P, Fonarow G, Ahmed A. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107(8):1208-14.
68. Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients from beta blockers to the same extent as the non-elderly? Meta- analysis of >12000 patients in large-scale clinical trials. Am J Cardiol. 2005;95:896-8. (Pubitemid 40386810)
69. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 2001;3:469-79. (Pubitemid 32776874)
70. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 1999;353:2001-7.
71. Packer M, Coats AJ, Fowler MB, et al. The effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8. (Pubitemid 32479962)
72. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivilol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25. (Pubitemid 40222359)
73. Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J. 2006;27:562-8.
74. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced heart failure. N Engl J Med. 2001;344:1659-67. (Pubitemid 32479963)
75. Domanski M, Krause-Steinrauf H, Goldman S, et al. Failure of benefit and early hazard of bucindolol for class IV heart failure. J Card Fail. 2003;9:266-77. (Pubitemid 37351802)
76. Anand I, Fiuzat M, O'Connor C, et al. Impact of baseline volume status and LVEF on all-cause mortality in the BEST trial. J Am Coll Cardiol 2010;55:A37, E360.
77. White M, Desai RV, Guichard JL, et al. Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified posthoc analysis of BEST. Can J Cardiol. 2012;28(3):354-9.
78. Maeder MT, Kaye DM. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced ejection versus preserved left ventricular ejection fraction. Int J Cardiol. 2012;155(2):249-56.
79. Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial. Lancet. 2010;376(9744):888-94.
80. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 2002;40:491-8. (Pubitemid 34833165)
81. Dobre D, Zannad F, Keteylaw SJ et al. Association between resting heart rate, chronotrophic index, and long-term outcomes in patients with heart failure receiving beta-blocker therapy: data from the HF - Action trial. Eur Heart J. 2013 Jan 12 (Epub ahead of print).
82. Jon deau G, Neuder Y, Eicher JC, et al. B-CONVINCED: Beta-blockers CONtinuation vs Interruption in patients with congestive heart failure hospitalized for a decompensation episode. Eur Heart J. 2009;30:2186-92.
83. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure and left ventricular ejection fraction ≥40 % treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;80(2):207-9. (Pubitemid 27329224)
84. Fosbol EL, Seibaek M, Brendorp B, et al. Long- term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the DIAMOND study. Int J Cardiol. 2010;140:279-86.
85. Leonetti LR, Celli V, et al. Carvedilol in elderly patients with chronic heart failure, a 12 weeks randomized, placebo controlled open trial. Arch Gerontol Geriatr. 1999;29:275-82.
86. Willemheimer R, van Veldhuisen DJ, Silke B, et al. Effect of survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112:2426-35. (Pubitemid 41504492)
87. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525-33.
88. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group Trial. Circulation. 2006;114:266-70. (Pubitemid 44264821)
89. Rich MW, McSherry F, Williford WO, Yusuf S, for the Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure. The DIG study. J Am Coll Cardiol. 2001;38:806-13. (Pubitemid 32835757)
90. Aronow WS. Appropriate use of digoxin in treating older nursing home patients with heart failure. J Am Med Dir Assoc. 2006;7:604-6. (Pubitemid 44767126)
91. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871-8. (Pubitemid 37430346)
92. Rathore SS, Wang Y, Krunholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-11. (Pubitemid 35239712)
93. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine and isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-10.
94. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide nitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-57. (Pubitemid 39482498)
95. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990;66:981-6. (Pubitemid 20360593)
96. Border JS, Bohm M, Ford I, et al. Effects of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J. 2012;33(22):2813-20.
97. Tousoulis D, Antoniades C, Vassiliadou C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail. 2005;7:1126-32. (Pubitemid 41721115)
98. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail. 2005;11:684-90. (Pubitemid 41797497)
99. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: comparison of medical therapy, pacing and defibrillation in chronic heart failure (COMPANION trial). J Card Fail. 2000;6(3):276-85.
100. Kjekshus J, Adetrei E, Barrios V, CORONA group, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-61. (Pubitemid 350190755)
101. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with cardiac heart failure (the GISSI-HF trial): a randomized, double- blind, placebo- controlled trial. Lancet. 2008;372(9645):1231-9.
102. Xu M, Yuan G, Wei F. Effect of atorvastatin in patients with chronic heart failure: insights from randomized clinical trials. Arch Med Sci. 2010;6(6):866-73.
103. Gastelurrutia P, Lupon J, De Antonio M, et al. Statins in heart failure: the paradox between large randomized clinical trials and real life. Mayo Clin Proc. 2012;87(6):555-60.
104. Fukuta H, Same DC, Brucks S, Little WC, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005;112:357-63. (Pubitemid 41022076)
105. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit. 2009;15:MS1-5.
106. Stys T, Lawson WE, Smaldone GC, Stys A. Does aspirin attenuate the beneficial effect of angiotensin converting enzyme inhibition in heart failure. Arch Intern Med. 2000;160(10):1409-13. (Pubitemid 30327442)
107. Al-Khadra AS, Salem DW, Rand WM, et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;31(4):7749-53. (Pubitemid 28186406)
108. Massie BM, Collins JF, Ammon SE, WATCH Trial Investigators, et al. Randomized trial of warfarin, aspirin and clopidogrel in patients with heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119(12):1616-24.
109. Homma S, Thompson LPJ, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366(20):1859- 69.
110. Shore S, Aggarwal, V, Zolty R. Chronic anticoagulation and long term mortality in patients presenting for heart failure with preserved ejection fraction (HFPEF). J Am Coll Cardiol 2012;59(13): E1038.
111. Talameh JH, McLeod HL, Adams KF Jr, Patterson JH. Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. J Card Fail. 2012;18(4):338-49.
112. Braunstein JB, Anderson GF, Gerstenblith G, et al. Non-cardiac co-morbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226-33. (Pubitemid 37188347)
113. Dahlstrom U. Frequent non-cardiac co-morbidities in patients with chronic heart failure. Eur J Heart Fail. 2005;7(3):309-16. (Pubitemid 40249523)
114. Mogensen UM, Ersbol M, Andersen M, et al. Clinical characteristics and major co-morbidities in heart failure patients more than 85 years of age compared with younger age group. Eur J Heart Fail. 2011;13(11):1216-23.
115. Stein GY, Kremer A, Shochat T, et al. The diversity of heart failure in a hospitalized population: the role of age. J Card Fail. 2012;18(8):645-53.
116. Caughey GE, Roughead EE, Shakib B, et al. Comorbidity and potential treatment conflicts in the elderly with heart failure: a retrospective, cross-sectional study of administrative claims data. Drugs Aging. 2011;28(7):575-81.
117. Kosiborod M, Smith GL, Radford MJ, et al. The prognostic importance of anemia in patients with heart failure. Am J Med. 2003;114:112-9. (Pubitemid 36183592)
118. Mascarenhas J, Lourenco P, Lopes R, et al. Chronic obstructive pulmonary disease in heart failure: prevalence, therapeutic and prognostic implications. Am Heart J. 2008;155:521-5. (Pubitemid 351255605)
119. Page J, Henry D. Consumption of NSAID's and the development of congestive heart failure in elderly patients: an under recognized public health problem. Arch Intern Med. 2000;160:777-84. (Pubitemid 30165238)
120. Witte KK, Clark AL. Beta-blockers and inspiratory pulmonary function in chronic heart failure. J Card Fail. 2005;11:112-6. (Pubitemid 40269785)
121. Packard K, Wurdeman R, Arouni A. ACE-inhibitor induced bronchial reactivity in patients with respiratory dysfunction. Ann Pharmacother. 2002;36:1058-67. (Pubitemid 34564392)
122. Maeder MT, Rickli H, Pristerer ME, TIME-CHF investigators, et al. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Am Heart J. 2012;163(3):407-14.
123. Anker SD, Comin Colet J, Filippatos G, for the Fair-HF Trial Investigators, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-48.
124. Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. JAMA. 1996;275:852-7.
125. Ko DT, Herbert PR, Coffey CS. Beta-blocker therapy and symptoms of depression, fatigue and sexual depression. JAMA. 2002;288(3):351-7. (Pubitemid 34761614)
126. Vaccarino V, Kasi SV, Abramson J, Krumholz HM. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol. 2001;38:199-205. (Pubitemid 32613851)
127. Elkman I, Fagerberg B, Skoog I. The clinical implications of cognitive impairment in elderly patients with chronic heart failure. J Cardiovasc Nurs. 2001;16:47-55.
128. Vogels RL, Scheltens P, Schroeder-Tanka JM, et al. Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail. 2007;9:440-9. (Pubitemid 46561483)
129. Tevendale E, Baxter J. Heart failure comorbidities at the end of life. Curr Opin Support Palliat Care. 2011;5(4):322-6.
130. Brunner-La Ricca HP, Rickenbacher P, Muzzarelli S, et al. End of life preferences of elderly patients with chronic heart failure. Eur Heart J. 2012;33:752-9.
131. Johnson D, Jin Y, Quan H, Cujec B. Beta-blockers and angiotensin converting enzyme inhibitors/receptor blockers prescription after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. J Am Coll Cardiol. 2003;42:1438-45. (Pubitemid 37267287)
132. Tsuyuki RT, Ackman ML, Montague TJ, et al. Effects of 1994 Canadian cardiovascular clinical practice guidelines for congestive heart failure. Can J Cardiol. 2002;18:147-52. (Pubitemid 34406617)
133. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population based cohort of 11942 elderly patients with heart failure. Am J Med. 2002;113:650-6. (Pubitemid 36015801)
134. Komadja M, Follath F, Swedberg K, et al. Study group on diagnosis of the working group on heart failure of the European Society of Cardiology. The Euroheart Failure Survey Programme - a survey on the quality of care among patients with heart failure in Europe: Part 2. Treatment. Eur Heart J. 2003;24:464-74. (Pubitemid 36286188)
135. Litaker LR, Chou JY. Patterns of pharmacologic treatment of congestive
136. Ahmed A. American College of Cardiology/American Heart Association chronic heart failure evaluation and management guidelines: relevance to geriatric practice. J Am Geriatr Soc. 2003;51:123-6.
137. Gambassi G, et al. Management of heart failure among very old persons living in long-term care: has the voice of trials spread? The SAGE Study Group, Part 1. Am Heart J. 2000;139(1):85-93. (Pubitemid 30043629)
138. Litaker LR, Chou JY. Patterns of pharmacologic treatment of congestive heart failure in elderly nursing home residents and related issues: a review of literature. Clin Ther. 2003;25(7):1918-35. (Pubitemid 36936589)
139. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J. 2009;30:478-86.
140. Mahony DO, Cherubini A, Petrovic M. Optimizing pharmacotherapy in older adults, a European perspective. Drugs Aging. 2012;29(6):423-5.
141. Konstam MA, Gheorghiade M, Burnett JC, et al. Effect of oral tolvaptan in patients hospitalized with worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319-31. (Pubitemid 46513233)
142. Dittrich HC, Gupta DK, Hack TC, et al. The effect of KW-3902, an adenosine A1 receptor antagonist on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007;13:609-17. (Pubitemid 47513547)
143. Funaya H, Kitakaze M, Node K, et al. Plasma adenosine levels increase in patients with chronic heart failure. Circulation. 1997;95:1363-5. (Pubitemid 27142790)
144. Nagayama T, Hsu S, Zhang M, et al. Sildenafil stops progressive chamber, cellular and molecular remodeling and improves calcium handling and function in heart with preexisting hypertrophy caused by pressure overload. J Am Coll Cardiol. 2009;53:207-15.
145. Guazzi M, Sumaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2138-44.
146. Andersen MJ, Ersbell M, Axelsson A, et al. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the sildenafil and diastolic dysfunction after acute myocardial infarction (SIDAMI) trial. Circulation. 2013;127(4):1200-8.
147. Redfield MM, Borlaug BA, Lewis GD, et al. Phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012;5:653-9.
148. Aronson D, Krum H. Novel therapies in acute and chronic heart failure. Pharmacol Ther. 2012;135(1):1-17.